NASDAQ:RNA

Avidity Biosciences Q4 2025 Earnings Results & Report

Avidity Biosciences logo
$6.43 -1.08 (-14.38%)
As of 04:00 PM Eastern

Avidity Biosciences missed analyst expectations on both earnings and revenue in its Q4 2025 results, released February 23, 2026. The company reported EPS of -$1.59 versus the -$1.24 consensus estimate, while revenue of $860 thousand fell short of the $1.98 million estimate by $1.12 million.

Earnings Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call
7:00 AM ET

Avidity Biosciences EPS Results

Actual EPS
-$1.59
Consensus EPS
-$1.24
Beat/Miss
Missed by -$0.35
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Avidity Biosciences Revenue Results

Actual Revenue
$860 thousand
Expected Revenue
$1.98 million
Beat/Miss
Missed by -$1.12 million
YoY Revenue Growth
N/A

Earnings Documents

Avidity Biosciences Q4 2025 Earnings FAQ

Avidity Biosciences (NASDAQ:RNA) reported earnings of -$1.59 per share for Q4 2025, missing the consensus estimate of -$1.24. The report was announced on Monday, February 23, 2026.

Avidity Biosciences reported revenue of $860 thousand for Q4 2025, against a consensus estimate of $1.98 million.

Avidity Biosciences Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Avidity Biosciences (RNA) Expected to Post Earnings on Thursday
See More Avidity Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avidity Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avidity Biosciences and other key companies, straight to your email.

About Avidity Biosciences

Avidity Biosciences (NASDAQ:RNA) is a biotechnology company focused on developing RNA-based medicines for diseases that affect muscle. Its Antibody Oligonucleotide Conjugate (AOC) platform combines antibodies with oligonucleotides to help deliver RNA-targeting treatments into muscle cells.

The company’s research and clinical pipeline has included programs for neuromuscular disorders such as myotonic dystrophy type 1 and Duchenne muscular dystrophy. Avidity was founded in 2012 and is based in San Diego, California.

View Avidity Biosciences Profile